Business News • PR NewsWire • Novartis analyses confirm benefit of Kymriah® with clinically meaningful rates of complete response seen in patients with certain advanced lymphomas

Novartis analyses confirm benefit of Kymriah® with clinically meaningful rates of complete response seen in patients with certain advanced lymphomas

Novartis analyses confirm benefit of Kymriah® with clinically meaningful rates of complete response seen in patients with certain advanced lymphomas

EAST HANOVER, N.J., Dec. 5, 2020 /PRNewswire/ -- Novartis announced analyses from two separate trials with Kymriah® (tisagenlecleucel) in patients with certain advanced lymphomas. In the interim analysis of the investigational Phase II ELARA study, Kymriah led to a complete response (CR)...

View More : https://www.prnewswire.com:443/news-releases/novartis-analyses-confirm-benefit-of-kymriah-with-clinically-meaningful-rat...

Releted News by prnewswire

Lancement de la première étude d'immunothérapie cellulaire UniCAR sur les tumeurs solides avancées

Sysmex Inostics Presents Data at the American Society of Hematology Annual Meeting Demonstrating Exquisite Sensitivity of SafeSEQ NGS Technology for Detection of Measurable Residual Disease in Acute Myeloid Leukemia

Genome Editing and Cellular Therapies Show Promise for Treating Blood Disorders, Cancers